FABP4 plasma levels are increased in familial combined hyperlipidemia

Journal of Lipid Research

Angel L. Garcia-Otín¹  Fernando Civeira²  Estibaliz Jarauta²  Iolanda Lázaro²  Lluís Masana³  Emilio Ros⁴  Juan F. Ascaso⁴  Núria Plana⁵  Raimón Ferré⁶  Anna Cabré⁶  Montserrat Cofán⁶ 

[1] CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid Spain;CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid Spain;Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario, Universitat de Valencia, Valencia Spain;Unidad de Lípidos y Riesgo Cardiovascular, Laboratorio de Investigación Molecular Servicio de Medicina Interna Hospital Universitario Miguel Servet, Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain;Unitat de Lípids, Servei d'Endocrinologia i Nutrició, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, Barcelona, Spain;Unitat de Recerca de Lípids i Arteriosclerosi, Universitat Rovira i Virgili, Servei de Medicina Interna, Hospital Universitari Sant Joan de Reus Reus, Spain;

关键词: dyslipidemia;    FCHL;    insulin resistance;    obesity;   

DOI  :  

来源: DOAJ

【 摘 要 】

The lipid profile of familial combined hyperlipidemia (FCHL) shares some characteristics with atherogenic dyslipidemia seen in diabetes, metabolic syndrome, and obesity. Adipocyte fatty acid-binding protein 4 (FABP4) appears to be a determinant of atherogenic dyslipidemia. We examined relationships between FABP4 plasma concentrations, dyslipidemia, and metabolic variables in patients with FCHL. We studied 273 unrelated FCHL patients and 118 control subjects. FABP4 was higher in FCHL than controls, with mean levels of 21.8 (10.1) μg/l and 19.2 (9.2) μg/l, respectively (adjusted P= 0.012). In FCHL, FABP4 correlated to body mass index (BMI), waist circumference, insulin levels, and homeostasis model assessment (HOMA) index (all P< 0.05), but not to lipid levels, whereas in obese patients, FABP4 correlated to triglyceride levels (r = 0.303, P= 0.014) and very low density lipoprotein size (r = 0.502, P = 0.001), as determined by nuclear magnetic resonance. Associations of FABP4 with BMI and waist circumference, but not with insulin levels, persisted in this subgroup. Plasma FABP4 does not influence the lipid phenotype of FCHL. In a small subgroup of obese FCHL, FABP4 levels were associated with triglyceride-rich lipoproteins independent of insulin resistance. These results support a hyperlipidemic mechanism of FCHL different from similar metabolic conditions where fat mass is strongly related to FABP4 and hypertriglyceridemia.

【 授权许可】

Unknown